Analysts Set Expectations for CRVS Q4 Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Equities researchers at HC Wainwright issued their Q4 2024 earnings estimates for shares of Corvus Pharmaceuticals in a report issued on Thursday, January 2nd. HC Wainwright analyst S. Lee forecasts that the company will post earnings per share of ($0.12) for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2029 earnings at $0.49 EPS.

Several other analysts have also recently commented on CRVS. Oppenheimer raised their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. LADENBURG THALM/SH SH lifted their price objective on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, September 16th. StockNews.com downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. Finally, Mizuho raised shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.38.

Corvus Pharmaceuticals Trading Up 7.4 %

Shares of NASDAQ:CRVS opened at $5.83 on Friday. The firm’s 50 day moving average is $7.67 and its two-hundred day moving average is $5.29. The firm has a market capitalization of $374.62 million, a P/E ratio of -6.27 and a beta of 1.05. Corvus Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $10.00.

Institutional Trading of Corvus Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Samlyn Capital LLC increased its holdings in shares of Corvus Pharmaceuticals by 160.7% in the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock valued at $11,144,000 after buying an additional 3,774,658 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Corvus Pharmaceuticals during the second quarter worth $136,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Corvus Pharmaceuticals during the second quarter valued at $44,000. Point72 Asset Management L.P. acquired a new position in shares of Corvus Pharmaceuticals in the 2nd quarter valued at $10,855,000. Finally, Avity Investment Management Inc. raised its holdings in Corvus Pharmaceuticals by 138.2% during the 3rd quarter. Avity Investment Management Inc. now owns 27,580 shares of the company’s stock worth $146,000 after buying an additional 16,000 shares during the period. 46.64% of the stock is owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.